Displaced lateral-end
fractures have a higher risk of nonunion after nonoperative treatment than do shaft fractures. However, nonunion is difficult to predict and may be asymptomatic in elderly individuals. The results of operative treatment are more unpredictable than they are for shaft fractures.”
“Oxycarotenoid lutein (3,3-dihydroxy-,epsilon-carotene) was checked for anticarcinogenic activity against N-nitrosodiethylamine-induced hepatocellular carcinoma (HCC) in rats. Lutein could significantly reduce the altered morphological and pathological changes in the liver induced by N-nitrosodiethylamine. Biochemical analysis of serum and tissues indicated that alanine transaminase, aspartate transaminase, and alkaline phosphatase were significantly elevated in the control Etomoxir clinical trial group and significantly reduced in the lutein-treated groups. These enzymes in liver tissue, which were
found to be elevated in the control group, were significantly reduced in the lutein-treated groups. Glutathione level was low in the control groups and it was found to be increased in the treated groups. The activity of -glutamyl GW4869 transpeptidase, a marker of cellular proliferation, was found to be significantly elevated in both the serum and the liver in the control group, which was reduced by the administration of lutein. Studies on the mechanism of action of lutein have indicated that it could significantly inhibit cytochrome P450 enzymes in vitro and in vivo in rats. Moreover, lutein could enhance the detoxifying enzymes glutathione-S-transferase DMXAA chemical structure and UDP glucuronyl transferase in vivo. Inhibition of carcinogenesis by lutein could be because of a combined effect of its antioxidant activity
along with the inhibition of cytochrome P450 enzymes and inducing detoxifying enzymes. Lutein is nontoxic and is one of the prime compounds in the chemoprevention trials of the future.”
“Repaglinide is a potent second generation oral hypoglycaemic agent widely used in treatment of non insulin dependent diabetic mellitus. The objective of the present study was to develop sustained release microspheres of repaglinide using ethyl cellulose and PEG 6000 as a matrix forming polymer. Microspheres were prepared by taking various concentrations of ethyl cellulose and PEG 6000 by spray drying technique. Prepared microspheres were evaluated for process yield, drug entrapment, particle size, SEM, FTIR, DSC and in vitro drug release. Process yield and drug entrapment was 40-45 % and 90-95 %, respectively. Particle size ranged in 5-22 mu m and SEM study showed spherical shape and rough surface of microspheres. FTIR study and DSC analysis revealed the stable nature and amorphous dispersion of drug in the polymer matrix. In vitro release studies indicate retardation of release upto 12 h which can control both fasting blood glucose level and postprandial blood glucose.